secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-06-08T10:11:32+00:00
Accession:  0001549595-26-000030
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix receives $700M upfront from Roche to co-develop BTK degrader bexobrutideg; potential $2.3B total
--------------------------------------------------------------------------------

- Upfront cash payment of $700 million; potential development, regulatory and sales milestones up to $2.3 billion total.
- Development costs shared 40% Nurix / 60% Roche; U.S. profits and losses split equally.
- Ex-U.S. royalties range from low-teens to high-teens on net sales; Roche leads commercialization outside U.S.
- Expansion into immunology and neurology: Phase 2 trials planned in multiple sclerosis and chronic spontaneous urticaria.
- Co-development and co-commercialization in U.S. across malignant hematology; Nurix becomes fully integrated biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/0001549595-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/nrix-20260606.htm
  HTML page:      https://secwatch.observer/filing/0001549595-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer